Accesso libero

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

Xing Li

Xing Li

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Cerca questo autore su
Sciendo|Google Scholar
Li, Xing
, 
Kaida Liu

Kaida Liu

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Cerca questo autore su
Sciendo|Google Scholar
Liu, Kaida
, 
Lidong Xing

Lidong Xing

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Cerca questo autore su
Sciendo|Google Scholar
Xing, Lidong
 e 
Boris Rubinsky

Boris Rubinsky

Department of Mechanical Engineering, University of California BerkeleyBerkeley, United States of America
Cerca questo autore su
Sciendo|Google Scholar
Rubinsky, Boris
  
04 set 2023
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Scarica la copertina
Categoria dell'articolo: Review
Pubblicato online: 04 set 2023
Pagine: 279 - 291
Ricevuto: 20 lug 2023
Accettato: 04 ago 2023
DOI: https://doi.org/10.2478/raon-2023-0044
Parole chiave
© 2023 Xing Li et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

The process of TTFields clinical trials on typical tumor types.
The process of TTFields clinical trials on typical tumor types.

FIGURE 2.

Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide

FIGURE 3.

Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928

FIGURE 4.

Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival

FIGURE 5.

Researches on potential mechanisms of TTFields action.
Researches on potential mechanisms of TTFields action.
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicina, Medicina clinica, Medicina interna, Ematologia, Oncologia, Radiologia
Feed RSS della rivista